Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.30 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.30 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.30 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372815 | 0.76 | LTA4H (0.40) | NPC1RAB9ABRD4GUCY1B2GUCY1A2 | |
| SCHEMBL372668 | 0.75 | ADRA1A (0.34) | ADRA1AADRA2AADRA1DADRA1BBRD4 | |
| SCHEMBL25286035 | 0.70 | NPC1 (0.40) | ADRA1AADRA2AADRA1DADRA1BNPC1 | |
| SCHEMBL18226969 | 0.70 | DPP4 (0.39) | — | |
| SCHEMBL7834048 | 0.69 | ADRA1A (0.48) | ADRA1AADRA2AADRA1DADRA1BBRD4 | |
| SCHEMBL27836284 | 0.68 | LTA4H (0.41) | NPC1RAB9ABRD4 | |
| SCHEMBL375075 | 0.68 | MPO (0.46) | — | |
| SCHEMBL22187760 | 0.67 | CTSA (0.44) | ADRA1AADRA2AADRA1DADRA1BBRD4 | |
| SCHEMBL1127573 | 0.67 | ADRA1A (0.38) | ADRA1AADRA2AADRA1DADRA1BNPC1 | |
| SCHEMBL13380088 | 0.67 | AKR1C3 (0.38) | ADRA1AADRA2AADRA1DADRA1BBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408756-B1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2408756-A1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | disclosed |
| US-7977362-B2 | Alpha-(N-benzenesulfonamido)cycloalkyl derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2010108067-A1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100240708-A1 | Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240708-A1 | Alpha-(N-Benzenesulfonamido)Cycloalkyl Derivatives | BACE1, BACE2, APP | ADRA1A 311/4885ADRA2A 383/4885ADRA1D 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.